VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Volution's limited third quarter 2022 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the start key followed by the number one on your touch-tone phone. If you would like to withdraw your question, please press the star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selection. This conference is being recorded today, November 15, 2022. I'd now like to turn the conference over to Scott Polo, Executive Vice President of Investor Relations. Please go ahead.

Thank you. operator and welcome everyone to today's earnings conference call for volition rx limited this call will cover volition's financial and operating results for the third quarter of 2022 along with a discussion of our recent activities and key upcoming milestones following our prepared remarks we will open the conference call to a question and answer session also on our call today i'm mr cameron reynolds president and chief executive officer Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary, and Mr. Terry Cuse, Chief Financial Officer. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements

made during the course of this conference call i'd now like to turn the call over to our president and chief executive officer mr cameron reynolds cameron thanks scott and thank you everyone for joining volition's third quarter 2022 earnings call today we especially appreciate as always your time given the busy earnings call season We will commence the call with Dr. Tom Butera, Chief Executive Officer of Volition Vet, to discuss the rollout of NUQ Vet via our global supply and licensing agreements. Then to Terry, who will provide a financial report. And finally, I will provide an update on the great progress the team have been making with regards to another of our key pillars, NUQ Nets, as well as a brief update on NUQ Cancer. So without further ado, I'll hand you across to Tom for an update on what's been an incredibly exciting time for our vet team.